<DOC>
	<DOCNO>NCT00962390</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness S-equol men benign prostatic hyperplasia .</brief_summary>
	<brief_title>Efficacy Safety S-Equol Men With Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>The study phase 2a , randomize , double blind , multicenter , placebo control , parallel group , proof concept study compare efficacy , safety , acceptability S-equol placebo patient benign prostatic hyperplasia . The study objective examine dose response 3 dose level S equol versus placebo prostate specific antigen concentration patient benign prostatic hyperplasia . The safety S-equol evaluate study .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Equol</mesh_term>
	<criteria>Is male &gt; 50 year age Screening . Has normal digital rectal exam exception prostate enlargement . Has suffer symptom BPH least 6 month Screening . Has prostate volume ≥ 20 mL ≤ 70 mL assess ultrasound . Has serum PSA concentration &gt; 1.5 ng/mL ≤ 10 ng/mL Screening . Has IPSS &gt; 13 Screening Baseline . Has Qmax &gt; 5 cc/sec &lt; 15 cc/sec void volume ≥ 125 cc Screening ( Baseline , applicable ) . Has know history allergic reaction clinically significant intolerance ingredient study drug . Neurogenic bladder dysfunction . Has bladder neck contracture urethral stricture . Has acute chronic prostatitis urinary tract infection . Has , history , prostate cancer carcinoma prostate suspect digital rectal exam transrectal ultrasound , serum PSA concentration &gt; 10 ng/mL ; patient PSA concentration &gt; 4 ng/mL ≤ 10 ng/mL must prostate cancer rule satisfaction investigator . Has residual void volume &gt; 250 mL . Has clinically significant unstable condition , opinion investigator , could compromise patient 's welfare , ability communicate study staff , otherwise contraindicate study participation . Shows presence manifest premalignant malignant disease except treated skin cancer ( except melanoma ) . Has history smoke 5 cigarette daily within year Screening . Has rest systolic blood pressure ( BP ) &gt; 160 mmHg &lt; 90 mmHg , diastolic BP &gt; 90 mmHg &lt; 60 mmHg Screening . Has bladder stone detect ultrasound . Has hematuria unknown etiology . Had previous prostate surgery invasive treatment BPH . Had prior radiation pelvis . Has Parkinson 's disease multiple sclerosis . Had stroke myocardial infarction within 5 month Baseline . Has abnormal screen electrocardiogram ( ECG ) unstable angina severe congestive heart failure . Has active liver disease renal insufficiency creatinine &gt; 1.7 mg/dL , clinically significant abnormal hemoglobin , white blood cell count , platelet count . Has history postural hypotension fall systolic BP &gt; 20 mm Hg 2 minute stand position . Received alpha blocker therapy within 28 day Baseline . Received androgen , anti androgen , 5 alpha reductase inhibitor , luteinizing hormone release hormone ( LHRH ) analog within 3 month Baseline . Received tricyclic antidepressant plant extract ( e.g. , saw palmetto ) within 1 month Baseline . Received sedating antihistamine , sympathomimetics , anticholinergic within 1 week Baseline . Has initiate new use ( i.e. , within past 4 week Screening ) otherwise stable dos phosphodiesterase 5 inhibitor 4 week Screening . Has know suspect history alcoholism drug abuse misuse within last 5 year . Is consider investigator , reason ( include , limited , risk describe precaution , warning , contraindication current version Clinical Investigator 's Brochure AUS 131 [ S equol ] ) , unsuitable candidate receive study drug . Has test positive urine drug screen .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>